Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer-Reference-Cited by-同舟云学术

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer

Published:2014-10 Issue:15 Volume:50 Page:2725-2734
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

García-Parra Jetzabel,Dalmases Alba,Morancho Beatriz,Arpí Oriol,Menendez Silvia,Sabbaghi MohammadA,Zazo Sandra,Chamizo Cristina,Madoz Juan,Eroles Pilar,Servitja Sonia,Tusquets Ignasi,Yelamos Jose,Lluch Ana,Arribas Joaquin,Rojo Federico,Rovira Ana,Albanell Joan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. The DNA damage response and cancer therapy;Lord;Nature,2012

2. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers;Fong;N Engl J Med,2009

3. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer;Domchek;J Clin Oncol,2011

4. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer;Juvekar;Cancer Discov,2012

5. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition;Ibrahim;Cancer Discov,2012

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study;The Breast;2024-10

2. Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models;Biomedicines;2023-07-25

3. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo;Gynecologic Oncology;2023-03

4. Implications of BRCA1 and BRCA2 Mutations in Mexico;BRCA1 and BRCA2 Mutations - Diagnostic and Therapeutic Implications;2023-01-18

5. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu;Gynecologic Oncology;2022-08